Abstract 145P
Background
Macrophages exert their functions mainly through SIRPa receptor, which interacts with CD47 on cellular targets. As many cancer cells overexpress CD47 to evade immune surveillance, blocking SIRPa-CD47 interaction represents a promising approach to control tumor progression. The clinical progress of anti-CD47 antibodies were hindered by either side effects or lacking appreciable efficacy. To overcome this dilemma, we engineered a SIRPa-fusion protein that exhibits superior efficacy against multiple tumor types while maintaining good safety profiles.
Methods
Using structure-guided protein engineering, we selected a SIRPa mutant that exhibited marked phagocytic abilities against tumors while maintaining good safety features on normal cells. To assess the efficacy of this molecule, it was tested in multiple xenograft mouse models alongside competing biologics currently in clinical trials. We also performed quantitative RNA transcriptional analysis to evaluate the changes in gene expression inside tumor and in the tumor microenvironment.
Results
Comparing to other clinical candidates, HCB101 triggered strong phagocytic reactions against tumor cells but not red blood cells. We have analyzed 14 human tumor xenograft models, HCB101 consistently showed excellent efficacy against heme and solid tumors, with tumor growth inhibition index ranging from 60-100% at the dose of 0.5-10mg/kg over placebo. We also observed an increase in M1/M2 macrophage ratio after the treatment with HCB101, which correlated with the observed anti-tumor efficacy. Quantitative RNA transcriptional analysis indicated that HCB101 triggered drastic changes in gene expression comparing to other competing molecules. This suggested a unique MOA underlying HCB101’s superior efficacy. There was no apparent adverse reaction observed during the toxicology studies, indicating a good safety profile.
Conclusions
Comparing to relevant clinical candidates, HCB101 exhibits superior efficacy in 14 different CDX models of hemotological and solid tumors while maintaining good safety profiles. It is a highly effective biologic with robust efficacy, both as monotherapy and in combination. Clinical trial of HCB101 is now in progress.
Clinical trial identification
NCT05892718.
Legal entity responsible for the study
HanchorBio, Inc.
Funding
HanchorBio, Inc.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
190P - Immune-related roles of B7H3 in glioblastoma
Presenter: Arnaud Simonet
Session: Poster Display
191P - Senolytic treatment remodels glioblastoma microenvironment
Presenter: Alexa Saliou
Session: Poster Display
192P - Analysis of Tumor-Associated Macrophages and Tumor-infiltrating Lymphocytes within the Tumor Microenvironment of Primary Tumors and Matched Brain Metastases
Presenter: Markus Kleinberger
Session: Poster Display
193P - Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibit anti-cancer immunity via CCL2
Presenter: Ronja Wieboldt
Session: Poster Display
194P - Achieving Reproducible Maturation Staging of Tertiary Lymphoid Structures: from Imaging Mass Cytometry Data to Pathology Applications
Presenter: Marion Le Rochais
Session: Poster Display
195P - IMMUcan - Toward a better understanding of the tumor microenvironment to inform precision oncology approaches.
Presenter: Marie Morfouace
Session: Poster Display
196P - Local glycan engineering induces systemic antitumor immune reactions via antigen cross-presentation
Presenter: Natalia Rodrigues Mantuano
Session: Poster Display
197P - Computational pathology pipeline enables quantification of intratumor heterogeneity and tumor-infiltrating lymphocyte score
Presenter: Daniel Tiezzi
Session: Poster Display
198P - Polarization of tumor-associated macrophages enhanced by 2-HP-_-cyclodextrin modified PLGA nanoparticles
Presenter: HAO YUAN
Session: Poster Display
199P - Scalable multiplexed image analysis across cancer types as part of the IMMUcan consortium
Presenter: Nils Eling
Session: Poster Display